USO DE ANÁLOGOS DE GLP-1 COMO FATOR PROTETOR CARDIOVASCULAR E RENAL
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists have become established as fundamental therapies in the management of type 2 diabetes mellitus and obesity, initially recognized for their effects on glycemic control and weight reduction. Robust evidence from randomized clinical trials and outcome studies has expanded this understanding, demonstrating that these agents confer clinically significant cardiovascular and renal benefits, independent of glycemic control alone. This chapter aimed to analyze the role of GLP-1 analogs as cardiovascular and renal protective factors in light of contemporary scientific evidence. This is a systematic review of the literature conducted using the PubMed database, including studies published over the past five years. The findings indicate a consistent reduction in major cardiovascular events, such as acute myocardial infarction and stroke, as well as a decrease in the progression of chronic kidney disease, with preservation of glomerular filtration rate and reduction in adverse renal outcomes. Recent trials have also demonstrated cardiovascular benefits in individuals with obesity and established cardiovascular disease, even in the absence of diabetes. It is concluded that GLP-1 analogs represent a therapeutic strategy with significant impact on reducing cardiovascular and renal morbidity and mortality, and should be considered central components in the integrated management of patients at high cardiometabolic risk.
Fields of Study & Subjects
Diabetes Treatment and Management
Chronic Kidney Disease and Diabetes
Pharmacology and Obesity Treatment
Publication details
- Pages
- 303–309
- Publication date
- 24 March 2026
- Language
- EN
- Document type
- Book chapter